Sector pending / Biological Products, Except Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

FRA/0GT stock hub

FRA/0GT has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/0GTis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.7B

Frankfurt Stock Exchange

Market data

Price

Recent price action with selectable time range.

FRA/0GTFRA/0GT

—

Loading chart…

In the news

Latest news · FRA/0GT

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-45.6

P25 n/aP50 n/aP75 n/a

ROIC-300.6

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/0GT market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

154

Groups with data

Currency

USD

Showing 154 of 154 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	DE
Employees	170
Employees Change	42%
Employees Change Percent	32.81
Enterprise value	EUR 1.4B
Exchange	Frankfurt Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Biological Products, Except Diagnostic Substances
Last refreshed	2026-05-10
Market cap	EUR 1.7B
Price	EUR 27.6
Price currency	EUR
Rev Per Employee	163,664.61x
Sic	2836
Symbol	fra/0GT
Website	https://www.stoketherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-8.46%
EV Earnings	-9.45x
EV/FCF	-10.86x
EV/Sales	51.03x
FCF yield	-7.36%
P/B ratio	5.08x
P/S ratio	62.54x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	100%
Gross Profit	EUR 27.8M
Gross Profit Growth	-83.2%
Gross Profit Growth Q	-96.07%
Gross Profit Growth3 Y	30.13%
Net Income	EUR -147.2M
Pretax Margin	-533.18%
Profit Per Employee	EUR -866,111
ROA	-27.24
Roa5y	-21.02
ROCE	-46.03
ROE	-45.58
Roe5y	-38.65
ROIC	-300.6

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	263.48%
Cagr3y	42.43%
Cagr5y	1.36%
Revenue Growth	-83.2x
Revenue Growth Q	-96.07x
Revenue Growth3 Y	30.13x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.08
Assets	EUR 384.5M
Cash	EUR 298M
Current Assets	EUR 310.9M
Current Liabilities	EUR 34.6M
Equity	EUR 342.5M
Interest Coverage	-20,582.3
Liabilities	EUR 42M
Long Term Assets	EUR 73.5M
Long Term Liabilities	EUR 7.4M
Net Cash	EUR 356.5M
Net Cash By Market Cap	EUR 20.49
Net Cash Growth	9.29%
Net Debt Equity	EUR -1.04
Tangible Book Value	EUR 342.5M
Tangible Book Value Per Share	EUR 5.5

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	8.99
Net Working Capital	EUR -15.3M
Quick ratio	8.57
Working Capital	EUR 282.6M
Working Capital Turnover	EUR 0.08

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-5.62%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	263.16%
200-day SMA	24.07
3Y total return	189.01%
50-day SMA	29.17
50-day SMA vs 200-day SMA	50over200
5Y total return	6.98%
All Time High	58
All Time High Change	-52.41%
All Time High Date	2021-01-20
All Time Low	3.16
All Time Low Change	773.42%
All Time Low Date	2023-10-30
ATR	0.65
Ch YTD	2.22
High	27.6
High52	32.8
High52 Date	2026-03-11
High52ch	-15.85%
Low	27.6
Low52	7.55
Low52 Date	2025-05-08
Low52ch	265.56%
Ma50ch	-5.4%
Price vs 200-day SMA	14.68%
RSI	43.7
RSI Monthly	69.31
RSI Weekly	54.62
Sharpe ratio	2.17x
Sortino ratio	4.05
Total Return	-5.62%
Tr YTD	2.22
Tr1m	-1.08%
Tr1w	-0.58%
Tr3m	5.34%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR -160.7M
Operating margin	-577.5

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	46,953,803%
Shares Insiders	3.85%
Shares Institutions	94.56%
Shares Qo Q	1.65%
Shares Yo Y	5.62%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR -157.8M
Average Volume	25.5x
Bv Per Share	5.5
CAPEX	EUR -755,418
Ch1m	-1.08
Ch1w	-0.58
Ch1y	263.2
Ch3m	5.34
Ch3y	189
Ch5y	6.98
Ch6m	44.5
Change	-0.72%
Change From Open	0
Close	27.8
Days Gap	-0.72
Depreciation Amortization	1,468,670.2
Earnings Date	2026-08-07
EBIT	EUR -160.7M
EBITDA	EUR -159.2M
EPS	EUR -2.43
F Score	2
FCF	EUR -128.1M
FCF EV Yield	-9.21x
Financing CF	156,410,617
Fiscal Year End	December
Founded	2,014
Income Tax	EUR -1.1M
Investing CF	-129,878,175
Is Primary Listing	0
Last Report Date	2026-03-31
Ma150	26.83
Ma150ch	2.86%
Ma20	29.03
Ma20ch	-4.92%
Net CF	-100,808,014
Next Earnings Date	2026-08-07
Open	27.6
Ppne	4,992,800.3
Price Date	2026-05-08
Ptbv Ratio	5.08
Relative Volume	20x
Revenue	27,822,984x
SBC By Revenue	106.73x
Share Based Comp	29,694,617
Tax By Revenue	-3.98x
Tr6m	44.5%

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/0GT pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/0GT stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/0GT?

Insider, institutional, and short-interest positioning.

Institutional ownership

+94.6%

Share of float held by funds and institutions

Insider ownership

+3.9%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+5.6%

Negative means the company is buying back shares.

Technical

FRA/0GT momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

43.7

Neutral momentum band

Price vs 200-day MA

+14.7%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

2.17

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/0GT

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/0GT stock rating?

fra/0GT is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/0GT analysis?

The full report lives at /stocks/fra/0GT/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/0GT?

The latest report frames fra/0GT around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/0GT page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.